Application of HMGA2 gene in polycystic ovary syndrome disease

A technology of HMGA2-IMP2 and uses, applied in the direction of determination/inspection of microorganisms, biochemical equipment and methods, material inspection products, etc.

Pending Publication Date: 2019-06-11
SHANDONG UNIV +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of IMP2 in granulosa cell (GC) proliferation has not been reported previously

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of HMGA2 gene in polycystic ovary syndrome disease
  • Application of HMGA2 gene in polycystic ovary syndrome disease
  • Application of HMGA2 gene in polycystic ovary syndrome disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Patient Recruitment

[0047] A total of 154 Han women were recruited from the Center for Reproductive Medicine of Shandong University, of which 96 were PCOS patients and the other 58 were controls. Each patient gave a formal written consent. PCOS patients were selected according to the Rotterdam criteria (25): oligo-and / or anovulation; clinical and / or biochemical indicators of hyperandrogenism; and exclusion of other hyperandrogen Polycystic ovary due to hyperprolactinemia, androgen-secreting tumors, Cushing's syndrome, and atypical congenital adrenal hyperplasia. All women were aged between 20 and 35 years and had at least two serum samples with FSH concentrations 1 ng / mL separated by ≥1 month. Control subjects were age-matched females with regular cycles, normal baseline endocrine parameters and bilateral antral follicle counts (single antral follicle count = 6-10), and no family history of diabetes or glucose disturbances. Exclusion criteria included current or re...

Embodiment 2

[0049] Embodiment 2 experimental method and reagent

[0050] Ovarian stimulation and collection of granulosa cells

[0051] Ovarian stimulation and oocyte collection were performed using a long-acting gonadotropin-releasing hormone agonist regimen (27). Ultrasound for follicular development and blood sampling for estradiol (E2) and progesterone (P4) levels were performed every 1-3 days. After sufficient follicle development, human chorionic gonadotropin (hCG) is administered. Oocyte retrieval was performed for follicles >15 mm in diameter by transvaginal ultrasound-guided acupuncture 36 hours after hCG administration. Within 3 days of egg retrieval, no more than 3 embryos are implanted into the uterine cavity. From the day of oocyte retrieval, women receive hCG or P4 treatment. Urine and serum tests for hCG were performed 14 days after embryo transfer. In the case of a positive hCG, an ultrasonography was performed 2 weeks later to confirm a clinical pregnancy. At the ti...

Embodiment 3

[0077]Embodiment 3PCOS patient and control experimenter's basic clinical index

[0078] PCOS-related clinical features were measured in control and patient samples (Table 1). The average BMI (kg / m2) of PCOS patients was 24.89, which was higher than that of controls (21.76; p<0.05). In women with PCOS, luteinizing hormone (LH), total testosterone (TT), anti-Müllerian hormone (AMH), fasting blood glucose (FPG), fasting insulin (FINS), HOMA-IR and other indicators were higher than those in the control group, And follicle stimulating hormone (FSH) decreased. There was no statistical difference in progesterone between the PCOS patient group and the control group.

[0079] Table 1 Clinical characteristics of the control group and patients

[0080]

[0081] All data are mean ± SD

[0082] BMI, body mass index; E2, estradiol; P4, progesterone; PRL, prolactin; T, testosterone; FPG, fasting plasma glucose; FINS, fasting insulin; HOMA-IR, homeostatic model assessment of insulin re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The present invention provides a method or a kit for diagnosing polycystic ovary syndrome by the detection of HMGA2-IMP2 pathway. The present invention also provides a method or a kit for diagnosing female granular cell abnormality by the detection of the HMGA2-IMP2 pathway.

Description

technical field [0001] The invention relates to the fields of molecular biology and disease gene research and diagnosis. Specifically, the present invention relates to genes related to polycystic ovary syndrome and the application of said genes in researching or diagnosing polycystic ovary syndrome. Background technique [0002] Polycystic ovary syndrome (PCOS) is a complex endocrine disease in women of reproductive age, with a worldwide prevalence of 6% to 8% (Ehrmann DA et al., Diabetes care 1999; 22:141-146). Polycystic ovary syndrome is characterized by hyperandrogenism, menstrual irregularities and polycystic ovarian morphology. The pathogenesis of PCOS is still not fully understood, and genetic predisposition has long been recognized, but there are complex interactions between genetic and environmental factors (Chen ZJ et al., Nature genetics 2011; 43:55-59). [0003] High mobility group protein A2, namely HMGA2 (high mobility group AT-hook 2), is a member of the HMG...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68
Inventor 陈子江刘洪彬赵涵李苗路钢
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap